These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36467807)

  • 1. A new aberrantly spliced
    Naumann N; Bross-Bach U; Seifarth W; Fabarius A; Hofmann WK; Saußele S; Spiess B
    EJHaem; 2022 Nov; 3(4):1339-1342. PubMed ID: 36467807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring.
    Crampe M; Haslam K; Kelly J; Conneally E; Langabeer SE
    Hematol Oncol Stem Cell Ther; 2017 Jun; 10(2):85-88. PubMed ID: 27013275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A unique BCR-ABL1 transcript with the insertion of intronic sequence from BCR and ABL1 genes in a patient with Philadelphia-positive chronic myeloid leukemia: a case study.
    Sadia H; Siddiqui RT; Nasim A
    Cancer Genet Cytogenet; 2010 Aug; 201(1):57-61. PubMed ID: 20633771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR-ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia.
    Vasconcelos AP; Azevedo IF; Melo FCBC; Neves WB; Azevedo ACAC; Melo RAM
    Genet Mol Res; 2017 Apr; 16(2):. PubMed ID: 28437552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of
    Uzoma IC; Taiwo IA; Nna EO; Durosinmi MA; Ukaejiofo EO
    Niger J Clin Pract; 2019 Jan; 22(1):51-55. PubMed ID: 30666020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD).
    Duan MH; Li H; Cai H
    Leuk Res; 2017 Aug; 59():8-11. PubMed ID: 28527402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review on characterization of BCR - ABL transcript variants for molecular monitoring of chronic myeloid leukemia phenotypes.
    Zenebe B; Nigussie H; Belay G; Seboka N
    Hematology; 2023 Dec; 28(1):2284038. PubMed ID: 37982440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel BCR-ABL1 fusion and leukemic mutations of SETBP1, PAX5, and TP53 detected by next generation sequencing in chronic myeloid leukemia.
    Fu S; Hu Y; Fu Y; Chen F; Liu X; Zhang M; Wang X; Tu S; Zhang J
    Cancer Biol Ther; 2016 Oct; 17(10):1003-1009. PubMed ID: 27611742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
    Rostami G; Hamid M; Jalaeikhoo H
    Gene; 2017 Sep; 627():202-206. PubMed ID: 28627443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel
    Jean J; Sukhanova M; Dittmann D; Gao J; Jennings LJ
    Case Rep Hematol; 2024; 2024():8486267. PubMed ID: 39183762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Recurrent Atypical e8a2 BCR::ABL1 Transcript with Insertion of an Inverted 55 Base Pair ABL1 Intron 1b Sequence: A Detailed Molecular Analysis.
    Burmeister T; Bullinger L; le Coutre P
    Acta Haematol; 2023; 146(5):413-418. PubMed ID: 37231781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR.
    Zagaria A; Anelli L; Coccaro N; Tota G; Casieri P; Cellamare A; Impera L; Brunetti C; Minervini A; Minervini CF; Delia M; Cumbo C; Orsini P; Specchia G; Albano F
    Virchows Arch; 2015 Sep; 467(3):357-63. PubMed ID: 26149409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variant-specific BCR::ABL1 quantification discrepancy in chronic myeloid leukemia.
    Jacobs K; Moerman A; Vandepoele K; Abeele TVD; De Mulder K; Steel E; Clauwaert M; Louagie H
    Int J Lab Hematol; 2024 Jun; ():. PubMed ID: 38840510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of
    Owojuyigbe TO; Durosinmi MA; Bolarinwa RAA; Salawu L; Akinola NO; Ademosun AA; Bosede OT
    Indian J Hematol Blood Transfus; 2020 Oct; 36(4):646-651. PubMed ID: 33100706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adult acute lymphoblastic leukemia with a rare b3a3 type BCR/ABL1 fusion transcript.
    Kurita D; Hatta Y; Hojo A; Kura Y; Sawada U; Kanda Y; Takei M
    Cancer Genet; 2016 Apr; 209(4):161-5. PubMed ID: 26854094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia.
    Moore FR; Rempfer CB; Press RD
    Methods Mol Biol; 2013; 999():1-23. PubMed ID: 23666687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chronic myeloid leukemia with variant e13a3 (b2a3) BCR-ABL1 as an ABL1 tyrosine kinase inhibitor-sensitive subtype].
    Togitani K; Asagiri T; Kamioka M; Kojima K
    Rinsho Ketsueki; 2021; 62(3):180-185. PubMed ID: 33828011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid decline of Philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3
    Massimino M; Stella S; Tirrò E; Consoli ML; Pennisi MS; Puma A; Vitale SR; Romano C; Zammit V; Stagno F; Di Raimondo F; Manzella L
    Oncol Lett; 2019 Sep; 18(3):2648-2653. PubMed ID: 31404304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytogenetic, fluorescence in situ hybridization, and genomic array characterization of chronic myeloid leukemia with cryptic BCR-ABL1 fusions.
    Shao L; Miller S; Keller-Ramey J; Zhang Y; Roulston D
    Cancer Genet; 2015; 208(7-8):396-403. PubMed ID: 26186983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the
    Moisoiu V; Teodorescu P; Parajdi L; Pasca S; Zdrenghea M; Dima D; Precup R; Tomuleasa C; Soverini S
    Front Oncol; 2019; 9():863. PubMed ID: 31608223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.